HTS Biosystems of Hopkinton, Mass., has appointed Masaaki Sasajima as head of HTS Asia, marking the company’s official foray into the Asian market.
Sasajima, who previously worked for the life science and diagnostics unit of Mitsubishi Chemical, will be in charge of developing the company’s business in Asia and managing its relationship with Mitsubishi Chemical, which has exclusive rights to distribute HTS’s surface plasmon resonance technology in Japan.
HTS is 73 percent owned by Minnesota-based Quantech and 18 percent owned by Applied Biosystems.
Molecular Staging of New Haven, Conn., has announced a handful of executive-level appointments.
Michael Egholm, previously group leader for Applied Biosystems’ peptide nucleic acids core, has joined Molecular Staging as vice president of research; F. Scott Reding, previously chief financial officer for Zonagen, was named CFO; Peter Fuller, who was previously senior vice president of business development at CuraGen, has been appointed to the same position at Molecular Staging; Steve Piccoli, previously, COO of Diagnostic Oncology CRO, has joined as vice president of diagnostics; and Jennifer Joiner, previously vice president of commercial operations for Bayer Diagnostics’ laboratory testing segment, has been named vice president of marketing and strategic planning.
Illumina of San Diego has elected R. Scott Greer, chairman and CEO of Abgenix, to its board of directors, replacing Charles Hartman, who did not stand for re-election.
Greer has been CEO of Abgenix since 1996. Prior to that he held senior positions with Cell Genesys. He has a bachelors degree in economics from Whitman College and an M.B.A. from Harvard University.